IMUNON to Host Virtual R&D Day on September 14th Beginning at 4:00 p.m. ET
Program will feature members of IMUNON executive management along with key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J. , Sept. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq:   IMNN) , a clinical-stage biotechnology company focused on developing DNA-mediated
September 7, 2023
IMUNON Expands Scientific Advisory Board with the Addition of Dr. Sachet Shukla
Renowned scientist will advise on the development of IMUNON’s FixPlas and IndiPlas modalities in immuno-oncology LAWRENCEVILLE, N.J. , Aug. 14, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy
August 14, 2023
Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
LAWRENCEVILLE, N.J. , June 26, 2023 (GLOBE NEWSWIRE) -- Imunon , Inc.  (NASDAQ: IMNN ), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant
June 26, 2023